You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国中药(00570.HK)以1.5人币受让化湿败毒颗粒临床试验批
阿思达克 03-30 18:31
中国中药(00570.HK)公布,与中国中医科学院签署《技术转让合同》,以1.5亿元人民币价格受让化湿败毒颗粒临床试验批件、专利及药品注册证书。

在此次新冠肺炎疫情中,中医药治疗应用广泛,彰显了中医药在应对新发突发重大公共卫生事件中的独特优势和作用。化湿败毒方是由中国中医科学院医疗科研团队在武汉抗击新冠肺炎疫情过程中结合临床实践优化而成,被列入第六版、第七版《新型冠状病毒肺炎诊疗方案》。

目前已开展临床前动物实验及临床观察研究,并正在进行前瞻性的随机对照临床试验,为化湿败毒颗粒的新药申报提供了确切临床疗效证据。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account